, Aug. 20, 2012
/PRNewswire/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has launched a new
product in the U.S. - ButequineTM
(phenylbutazone paste) - for the relief of inflammatory conditions
associated with the musculoskeletal system in horses. This is a
proprietary product of Bioniche that is manufactured by Med-Pharmex
Inc., a U.S.-based contract manufacturer.
Bioniche has also acquired exclusive Canadian distribution rights to an
additional six products from Med-Pharmex, including topical Dermal
products for dogs and cats, an anti-diarrheal product for dogs, cats,
horses and cattle, and nutritional supplements for calves. Med-Pharmex
will manufacture all of these products for Bioniche.
About ButequineTM Paste
ButequineTM Paste is an FDA-approved product for horses that is administered orally
by syringe. Phenylbutazone is a non-steroidal anti-inflammatory drug
(NSAID). The product has a dose volume which is easy to administer, and
it is cost-competitive. Its green apple flavour is palatable and easily
ingested by horses.
"Bioniche Animal Health has been selling this product successfully in
Canada for several years," said Mr. Andrew Grant, President of Bioniche
Animal Health (global). "We expect U.S. equine veterinarians to be very
receptive to ButequineTM Paste, and we expect to see significant market penetration over the
next two years."
About the Med-Pharmex Products for Canada
Bioniche will be registering and selling six new Med-Pharmex products in
Canada. "Once registered, these products will become important
additions to the Bioniche Animal Health product line for both large and
small animal veterinarians as they are high-volume, high-value products
that are used in everyday veterinary care," said Mr. Grant.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Animal Health develops, manufactures and markets veterinary
biopharmaceutical products worldwide. In North America, it has
development, manufacturing and marketing facilities in Belleville,
Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington,
U.S.A. In Australia, business is conducted from two sites: Sydney, New
South Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2011. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.